Header Logo

Connection

Johnny Mahlangu to Aged

Back to Details
This is a "connection" page, showing publications Johnny Mahlangu has written about Aged.
Johnny Mahlangu
Connection Strength
1,257
Aged
  1. BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for =2 years. Eur J Haematol. 2020 Jun; 104(6):594-601.
    View in: PubMed
    Score: 0,121
  2. Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS). Haemophilia. 2019 May; 25(3):382-391.
    View in: PubMed
    Score: 0,113
  3. Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting. Haemophilia. 2019 Mar; 25(2):213-220.
    View in: PubMed
    Score: 0,112
  4. Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study. Haemophilia. 2018 Nov; 24(6):921-929.
    View in: PubMed
    Score: 0,109
  5. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018 08 30; 379(9):811-822.
    View in: PubMed
    Score: 0,108
  6. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. Haemophilia. 2017 Jan; 23(1):67-76.
    View in: PubMed
    Score: 0,094
  7. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014 Jan 16; 123(3):317-25.
    View in: PubMed
    Score: 0,078
  8. Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia. J Thromb Haemost. 2012 May; 10(5):773-80.
    View in: PubMed
    Score: 0,070
  9. A cohort study of the relationship between anaemia, mean corpuscular volume and mortality among a CKD population in South Africa. Afr Health Sci. 2021 Dec; 21(4):1764-1775.
    View in: PubMed
    Score: 0,034
  10. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021 04 22; 137(16):2231-2242.
    View in: PubMed
    Score: 0,033
  11. Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study. Haemophilia. 2021 May; 27(3):398-407.
    View in: PubMed
    Score: 0,032
  12. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia. 2020 May; 26(3):494-502.
    View in: PubMed
    Score: 0,030
  13. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia. 2019 Jan; 25(1):33-44.
    View in: PubMed
    Score: 0,027
  14. Utility of reticulocyte haemoglobin content and percentage hypochromic red cells as markers of iron deficiency anaemia among black CKD patients in South Africa. PLoS One. 2018; 13(10):e0204899.
    View in: PubMed
    Score: 0,027
  15. Evaluation of the self-administered bleeding assessment tool (Self-BAT) in haemophilia carriers and correlations with quality of life. Haemophilia. 2017 11; 23(6):e536-e538.
    View in: PubMed
    Score: 0,025
  16. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 08 31; 377(9):809-818.
    View in: PubMed
    Score: 0,025
  17. Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study. Haemophilia. 2016 Nov; 22(6):912-918.
    View in: PubMed
    Score: 0,024
  18. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia. 2016 Nov; 22(6):866-872.
    View in: PubMed
    Score: 0,023
  19. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016 May 26; 374(21):2054-64.
    View in: PubMed
    Score: 0,023
  20. Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4). Thromb Res. 2016 May; 141:69-76.
    View in: PubMed
    Score: 0,023
  21. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015 May; 13(5):743-54.
    View in: PubMed
    Score: 0,021
  22. Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey. Haemophilia. 2015 Sep; 21(5):589-97.
    View in: PubMed
    Score: 0,021
  23. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014 Dec 18; 124(26):3880-6.
    View in: PubMed
    Score: 0,021
  24. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. J Thromb Haemost. 2014 Aug; 12(8):1244-53.
    View in: PubMed
    Score: 0,020
  25. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013 Dec 12; 369(24):2313-23.
    View in: PubMed
    Score: 0,020
  26. Hepatitis C virus genotypes in two different patient cohorts in Johannesburg, South Africa. Arch Virol. 2008; 153(11):2049-58.
    View in: PubMed
    Score: 0,014
  27. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and multiple myeloma in South Africa. Diagn Mol Pathol. 2001 Jun; 10(2):95-9.
    View in: PubMed
    Score: 0,008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.